Trial: 201905001

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors

Phase

II

Principal Investigator

Waqar, Saiama

Disease Site

Corpus Uteri; Ill-Defined Sites; Lip, Oral Cavity and Pharynx; Liver; Lung; Lung Cancer – Non-small Cell; Lung Cancer – Small Cell

Learn more about this study at: clinicaltrials.gov